[Status quo of experimental and clinical studies in retarding kidney damage of chronic nephropathy by ligustrazine].
Cao
W F
WF
Li
R H
RH
Chen
B X
BX
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D016166:Free Radical Scavengers / Q000494:pharmacology; D005923:Glomerulosclerosis, Focal Segmental / Q000188:drug therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011719:Pyrazines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D016166:Free Radical Scavengers; D010975:Platelet Aggregation Inhibitors; D011719:Pyrazines; C017953:tetramethylpyrazine